USFDA inspections to be less disruptive for Indian pharma sector: Report
Indian pharma companies have increasingly de-risked their operations by slowly and steadily increasing sales to non-US markets, says India Ratings and Research.
pharma
January 2023
December 2022
Lupin launches asthma drug DIFIZMA; stock gains
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
Budget 2023 may offer Research Linked Incentive scheme for Indian pharma
RLI is expected to provide an extra financial cushion, in addition to the existing R&D sops available to pharmaceutical and biotech companies operating in India.
Suven Pharma stock rises 4% on acquisition by Advent International
Advent plans to merge its portfolio company Cohance Lifesciences with Suven to build an end-to-end CDMO and merchant API.
Lupin recalls blood pressure tablets in U.S.; stock up 3%
Lupin Pharmaceuticals Inc., the U.S. arm of the drug major, is voluntarily recalling four lots of Quinapril Tablets due to the presence of nitrosamine impurity.
Glenmark Pharma surges 6% on launching type 2 diabetes drug
Glenmark has launched Zita‐PioMet, India’s first triple fixed-dose combination for high insulin‐resistant type 2 diabetes.
Sun Pharma gets U.S. FDA warning for Halol facility; share falls 2%
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Glenmark Pharma drops 5% on U.S. FDA warning for Goa facility
The U.S. drug regulator has pointed out various lapses at Glenmark Pharma’s Goa facility, which produces drug formulations.
Orchid Pharma shares gain 3% on board’s nod to raise ₹500 cr via QIP
Orchid Pharma stock trades 12% lower than its 52-week high of ₹463.05, while it has surged 56% against its 52-week low of ₹260.20.
What’s behind Indian pharma cos’ global acquisition spree
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
